View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2015	Mar. 10, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		55,482,238
Entity Public Float			$ 298,662,067

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
CURRENT ASSETS:
Cash	$ 94,094	$ 92,867
Short-term investments	7,225	5,000
Accounts receivable, net of allowance for doubtful accounts of $798 and $533	19,265	16,138
Inventories	13,242	15,763
Prepaid expenses	1,533	1,140
Other current assets	1,355	306
Total current assets	136,714	131,214
PROPERTY AND EQUIPMENT, net	20,083	17,934
INTANGIBLE ASSETS, net	12,591	17,505
GOODWILL	18,250	21,734
OTHER ASSETS	1,683	1,246
TOTAL ASSETS	189,321	189,633
CURRENT LIABILITIES:
Accounts payable	5,087	7,148
Deferred revenue	9,735	8,043
Deferred income taxes		139
Accrued expenses	10,412	11,132
Total current liabilities	25,234	26,462
OTHER LIABILITIES	1,768	1,234
DEFERRED INCOME TAXES	2,883	3,236
COMMITMENTS AND CONTINGENCIES (Note 11)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 55,705 and 56,187 shares issued and outstanding	0	0
Additional paid-in capital	345,253	344,894
Accumulated other comprehensive loss	(15,639)	(7,848)
Accumulated deficit	(170,178)	(178,345)
Total stockholders' equity	159,436	158,701
Total liabilities and stockholders' equity	$ 189,321	$ 189,633

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 798	$ 533
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	55,705,000	56,187,000
Common stock, shares outstanding	55,705,000	56,187,000

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
NET REVENUES:
Product	$ 104,458	$ 98,894	$ 98,317
Other	15,261	7,570	623
Total revenue	119,719	106,464	98,940
COST OF PRODUCTS SOLD	39,426	39,840	40,351
Gross profit	80,293	66,624	58,589
OPERATING EXPENSES:
Research and development	11,654	12,058	10,932
Sales and marketing	35,088	41,118	46,465
General and administrative	25,493	23,750	21,654
Gain on contract termination settlement		(5,500)	(8,300)
Total operating expenses	72,235	71,426	70,751
Operating income (loss)	8,058	(4,802)	(12,162)
OTHER INCOME	774	531	200
Income (loss) before income taxes	8,832	(4,271)	(11,962)
INCOME TAX EXPENSE (BENEFIT)	665	343	(772)
NET INCOME (LOSS)	$ 8,167	$ (4,614)	$ (11,190)
EARNINGS (LOSS) PER SHARE:
BASIC	$ 0.14	$ (0.08)	$ (0.20)
DILUTED	$ 0.14	$ (0.08)	$ (0.20)
SHARES USED IN COMPUTING EARNINGS (LOSS) PER SHARE:
BASIC	56,397	55,949	55,555
DILUTED	56,846	55,949	55,555

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ 8,167	$ (4,614)	$ (11,190)
OTHER COMPREHENSIVE LOSS
Currency translation adjustments	(7,791)	(4,051)	(3,131)
COMPREHENSIVE INCOME (LOSS)	$ 376	$ (8,665)	$ (14,321)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Beginning Balance at Jan. 01, 2013	$ 170,315		$ 333,522	$ (666)	$ (162,541)
Beginning Balance, Shares at Jan. 01, 2013		55,281
Common stock issued upon exercise of options	$ 409		409
Common stock issued upon exercise of options, Shares	80	80
Vesting of restricted stock	$ 0	$ 0	0	0	0
Vesting of restricted stock, Shares		395
Purchase and retirement of common shares	(829)		(829)
Purchase and retirement of common shares, Shares		(124)
Compensation cost for restricted stock	2,878		2,878
Compensation cost for stock option grants	2,694		2,694
NET INCOME (LOSS)	(11,190)				(11,190)
Currency translation adjustments	(3,131)			(3,131)
Ending Balance at Dec. 31, 2013	161,146		338,674	(3,797)	(173,731)
Ending Balance, Shares at Dec. 31, 2013		55,632
Common stock issued upon exercise of options	$ 1,115		1,115
Common stock issued upon exercise of options, Shares	249	249
Vesting of restricted stock	$ 0	$ 0	0	0	0
Vesting of restricted stock, Shares		428
Purchase and retirement of common shares	(639)		(639)
Purchase and retirement of common shares, Shares		(122)
Compensation cost for restricted stock	2,663		2,663
Compensation cost for stock option grants	3,081		3,081
NET INCOME (LOSS)	(4,614)				(4,614)
Currency translation adjustments	(4,051)			(4,051)
Ending Balance at Dec. 31, 2014	158,701		344,894	(7,848)	(178,345)
Ending Balance, Shares at Dec. 31, 2014		56,187
Common stock issued upon exercise of options	$ 404		404
Common stock issued upon exercise of options, Shares	74	74
Vesting of restricted stock	$ 0	$ 0	0	0	0
Vesting of restricted stock, Shares		354
Purchase and retirement of common shares	(6,090)		(6,090)
Purchase and retirement of common shares, Shares		(910)
Compensation cost for restricted stock	2,642		2,642
Compensation cost for stock option grants	3,403		3,403
NET INCOME (LOSS)	8,167				8,167
Currency translation adjustments	(7,791)			(7,791)
Ending Balance at Dec. 31, 2015	$ 159,436		$ 345,253	$ (15,639)	$ (170,178)
Ending Balance, Shares at Dec. 31, 2015		55,705

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
OPERATING ACTIVITIES:
NET INCOME (LOSS)	$ 8,167	$ (4,614)	$ (11,190)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation	6,045	5,744	5,572
Depreciation and amortization	5,696	6,307	6,552
Deferred rent	110
Unrealized foreign currency (gain) loss	367	(305)	49
Loss on sale of fixed assets	80
Deferred income taxes	48	294	(772)
Changes in assets and liabilities
Accounts receivable	(3,739)	(3,381)	4,337
Inventories	2,348	(4,401)	1,268
Prepaid expenses and other assets	(1,415)	475	51
Accounts payable	(2,648)	2,194	1,510
Deferred revenue	1,706	6,943	(4,365)
Accrued expenses and other liabilities	(992)	(1,730)	5,373
Net cash provided by operating activities	15,773	7,526	8,385
INVESTING ACTIVITIES:
Purchases of short-term investments	(26,895)	(9,407)
Proceeds from maturities of short-term investments	23,934	4,432
Purchases of property and equipment	(3,744)	(3,005)	(2,462)
Net cash used in investing activities	(6,705)	(7,980)	(2,462)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	404	1,115	409
Repurchase of common stock	(6,090)	(639)	(829)
Net cash provided by (used in) financing activities	(5,686)	476	(420)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(2,155)	(346)	(200)
NET INCREASE (DECREASE) IN CASH	1,227	(324)	5,303
CASH, BEGINNING OF PERIOD	92,867	93,191	87,888
CASH, END OF PERIOD	$ 94,094	$ 92,867	$ 93,191

The Company	12 Months Ended
The Company	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. THE COMPANY: We develop, manufacture, market and sell diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care, tests that are processed in a laboratory, and a rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market. We also manufacture and sell oral fluid collection devices used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, animal genetics, and microbiome markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Supplemental Cash Flow Information

In 2015, 2014 and 2013, we paid income taxes of $719, $31 and $27, respectively.

In 2015, 2014 and 2013, we recorded through the consolidated statements of operations an increase in our allowance for doubtful accounts of $341, $253 and $18, respectively, and we had no material write-offs against the allowance for doubtful account in 2015, 2014, or 2013.

As of December 31, 2015 and 2014, we had accruals for purchases of property and equipment of $1,370 and $217, respectively. We had no accruals for purchases of property and equipment as of December 31, 2013.

Short-Term Investments

We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive income (loss).

Accounts Receivable

Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Inventories

Inventories are stated at the lower of cost or market determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based primarily on the estimated forecast of product sales. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates. In addition to reserving for these items identified through specific identification procedures, we also reserve for unidentified scrap or spoilage under a fixed-formula methodology.

Property and Equipment

Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations.

Intangible Assets

Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of one to fifteen years.

Goodwill

Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with the respective carrying values.

We performed our annual impairment assessment as of July 31, 2015 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of December 31, 2015, we believe no indicators of impairment exist.

Impairment of Long-Lived Assets

We assess the recoverability of the our long-lived assets, which include property and equipment and intangible assets, by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets.

Revenue Recognition

We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick^®In-Home HIV test, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We began selling our OraQuick^® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue practices with respect to the OraQuick^® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick^® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result we initially did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at the gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the retail customer either in a store or over the internet. With the passage of time, however, we concluded that we had sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors.

Our net revenues recorded on sales of the OraQuick^® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. Some of these allowances are estimates established by management, based upon currently available information, and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations.

Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. It is recorded as other revenue in our statements of operations.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie to co-promote our OraQuick^® HCV test in the United States. The product is used to test individuals at-risk for the hepatitis C virus. We are responsible for manufacturing and selling the product into all markets covered by this agreement.

Pursuant to the Co-Promotion Agreement, we have granted exclusive co-promotion rights for the OraQuick^® HCV test in certain markets to AbbVie and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database is being used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick^® HCV test. We have also jointly agreed with AbbVie to co-promote our OraQuick^® HCV test in certain market segments.

Under the terms of this agreement, which runs through December 31, 2019, we are eligible to receive up to $75,000 in aggregate payments. We are recognizing these payments ratably on a monthly basis over the term of the agreement. In addition, if certain performance-based milestones are achieved, we may be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the term of the agreement. The first performance-based milestone period ended on December 31, 2015 and we did not achieve this milestone during this period. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Under certain circumstances, either party may terminate the agreement before its expiration and such a termination could occur as early as December 31, 2016. Amounts related to this agreement are recorded as other revenue in our statements of operations.

On June 12, 2015, we were awarded a grant for up to $10,400 in total funding from BARDA related to the development of our OraQuick^® Ebola Rapid Antigen test. The three-year, multi-phased grant includes an initial commitment of $1,800 and options for up to an additional $8,600 to fund certain clinical and regulatory activities. In September 2015, BARDA exercised an option to provide $7,200 in additional funding for the development of our OraQuick^® Ebola Rapid Antigen test. Amounts related to this grant are recorded as other revenue in our statement of operations as the activities are being performed and the related costs are incurred. During 2015, $1,783 was recognized in connection with this grant.

Customer Sales Returns and Allowances

We do not grant product return rights to our customers for any product, except for our OraQuick^® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick^® In-Home HIV product revenues in our consolidated statement of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of December 31, 2015 and 2014, the reserve for sales returns and allowances was $310 and $437, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Deferred Revenue

We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2015 and 2014 includes customer prepayments of $784 and $613, respectively. Deferred revenue as of December 31, 2015 and 2014 also includes $8,951 and $7,430, respectively, from AbbVie, which represents the excess of the payments received from AbbVie over the amounts earned and recognized ratably in our consolidated statement of operations.

Customer and Vendor Concentrations

We had no significant concentrations in accounts receivable as of December 31, 2015 and 2014. One of our customers accounted for approximately 12% of our net consolidated revenues for the year ended December 31, 2015. We had no significant concentrations in net consolidated revenues for the years ended December 31, 2014 or 2013.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Research and Development

Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2015, 2014, and 2013, we incurred $623, $6,910, and $17,142, respectively, in advertising expenses.

Stock-Based Compensation

We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue restricted stock, we issue new shares rather than purchase shares on the open market.

Income Taxes

We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

We assess the realizability of our net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, we reduce our net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of our net operating loss carryforwards.

Foreign Currency Translation

The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in the statement of operations in the period in which the change occurs. Net foreign exchange gains resulting from foreign currency transactions that are included in other income in our consolidated statement of operations were $1,005, $273, and $68 for the years ended December 31, 2105, 2014, and 2013, respectively.

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options and unvested restricted stock, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings (loss) per share are as follows:


	Year ended December 31,
	2015		2014			2013
Net income (loss)	$	8,167	$	(4,614	)	$	(11,190	)

Weighted average number of common shares outstanding:
Basic		56,397		55,949			55,555
Dilutive effect of stock options and restricted stock		449		—			—

Diluted		56,846		55,949			55,555

Earnings (loss) per share:
Basic	$	0.14	$	(0.08	)	$	(0.20	)

Diluted	$	0.14	$	(0.08	)	$	(0.20	)

For the years ended December 31, 2015, 2014, and 2013, outstanding common stock options and unvested restricted stock representing 4,756, 6,447, and 5,924 shares, respectively, were excluded from the computation of diluted earnings (loss) per share as their inclusion would have been anti-dilutive.

Accumulated Other Comprehensive Loss

We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.

Our accumulated other comprehensive loss for 2015, 2014, and 2013 consisted of foreign currency translation adjustments.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The negative $7,791, $4,051 and $3,131 currency translation adjustments recorded in 2015, 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars.

Fair Value of Financial Instruments

As of December 31, 2015 and 2014, the carrying values of cash, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:

Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3:

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Included in cash and cash equivalents at December 31, 2015 and 2014, was $65,509 and $64,361 invested in a government money market fund. This fund has investments in government securities and is a Level I instrument.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of December 31, 2015 and 2014 was $1,324 and $1,234, respectively, and was calculated using the quoted market price of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.

Our available-for-sale securities as of December 31, 2015 and 2014 consisted of guaranteed investment certificates with amortized cost and fair value of $7,225 and $5,000, respectively and are measured as Level 1 instruments.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, with early adoption permitted. We are still evaluating the effects, if any, which adoption of this guidance will have on our consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory, which requires an entity that uses the first-in, first-out method for inventory measurement to report inventory cost at the lower of cost and net realizable value versus the current measurement principle of lower of cost or market. The ASU requires prospective adoption for inventory measurements for fiscal years beginning after December 15, 2016. Early adoption is permitted. We are evaluating the effect that ASU 2015-11 may have on our consolidated financial statements and related disclosures.

In November 2015, the FASB issued ASU 2015-17, which requires entities with a classified balance sheet to present all deferred tax assets and liabilities as noncurrent. The ASU is effective for interim and annual periods in fiscal years beginning after December 15, 2016. Early adoption is permitted. The Company has chosen to early adopt ASU 2015-17 and the impact is presented in the consolidated financial statements and related disclosures as of December 31, 2015. Prior years were not retrospectively adjusted.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires entities to begin recording assets and liabilities from leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, using a modified retrospective approach. Early adoption is permitted. We are evaluating the effect that ASU 2016-02 may have on our consolidated financial statements and related disclosures.

Inventories

12 Months Ended

Dec. 31, 2015

Inventory Disclosure [Abstract]

Inventories

3. INVENTORIES:


	December 31,
	2015		2014
Raw materials	$	7,895	$	8,539
Work in process		333		898
Finished goods		5,014		6,326

	$	13,242	$	15,763

Property and Equipment

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment

4. PROPERTY AND EQUIPMENT:


	December 31,
	2015			2014
Land	$	1,118		$	1,118
Buildings and improvements		18,549			18,168
Machinery and equipment		21,263			20,768
Computer equipment and software		7,644			7,238
Furniture and fixtures		1,584			1,765
Construction in progress		2,938			293

		53,096			49,350
Less accumulated depreciation		(33,013	)		(31,416	)

	$	20,083		$	17,934

Depreciation expense was $2,992, $3,123, and $3,026 for 2015, 2014, and 2013, respectively.

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

5. GOODWILL AND OTHER INTANGIBLE ASSETS:

The changes in goodwill are as follows:


	December 31,
	2015			2014
Balance as of January 1	$	21,734		$	23,782
Decrease related to foreign currency translation		(3,484	)		(2,048	)

Balance as of December 31	$	18,250		$	21,734

Intangible assets consist of the following:


		December 31, 2015
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	9,051	$	(3,818	)	$	5,233
Patents and product rights	10		5,400		(3,358	)		2,042
Acquired technology	7		7,030		(4,172	)		2,858
Tradename	15		3,469		(1,011	)		2,458

		$	24,950	$	(12,359	)	$	12,591


		December 31, 2014
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	10,779	$	(3,508	)	$	7,271
Patents and product rights	3-10		10,449		(7,957	)		2,492
Acquired technology	7		8,372		(3,833	)		4,539
Tradename	15		4,132		(929	)		3,203

		$	33,732	$	(16,227	)	$	17,505

Patents and products rights are made up of the following:


	December 31,
	2015			2014
HIV-related	$	900		$	1,900
HCV-related		4,500			4,500
Lateral flow-related		—			1,500
Cryosurgery-related		—			2,549

		5,400			10,449
Less accumulated amortization		(3,358	)		(7,957	)

	$	2,042		$	2,492

Amortization expense for 2015, 2014, and 2013 was $2,704, $3,184, and $3,526, respectively.

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2016	$	2,704
2017		2,704
2018		2,701
2019		1,659
2020		1,451
Beyond		1,372

	$	12,591

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Expenses

12 Months Ended

Dec. 31, 2015

Payables and Accruals [Abstract]

Accrued Expenses

6. ACCRUED EXPENSES:


	December 31,
	2015		2014
Payroll and related benefits	$	6,311	$	6,620
Professional fees		1,014		480
Royalties		819		2,285
Other		2,268		1,747

	$	10,412	$	11,132

Income Taxes

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes

7. INCOME TAXES:

Income (loss) before income tax expense (benefit) consists of the following:


	Years Ended December 31,
	2015		2014 ⁽¹⁾			2013 ⁽¹⁾
United States	$	5,302	$	(6,156	)	$	(10,554	)
Canada		3,530		1,885			(1,408	)

	$	8,832	$	(4,271	)	$	(11,962	)

⁽¹⁾

Prior period amounts have been reclassified to conform to current year presentation.

The components of the income tax expense (benefit) are as follows:


	Years Ended December 31,
	2015			2014			2013
Current
Federal	$	—		$	—		$	—
State		—			—			—
Canada		617			49			—

		617			49			—

Deferred
Federal		1,511			(2,248	)		(4,280	)
State		311			(827	)		(323	)
Canada		48			294			(772	)

		1,870			(2,781	)		(5,375	)
Increase (decrease) in valuation allowance		(1,822	)		3,075			4,603

		48			294			(772	)

Total income tax expense (benefit)	$	665		$	343		$	(772	)

For the years ended December 31, 2015 and 2014, we recorded foreign tax expense of $665 and $343, respectively. For the year ended December 31, 2013, we recorded foreign tax benefits of $772 associated with certain Canadian research and development and investment tax credits. The income tax benefit associated with DNAG was considered realizable based upon the estimated scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG.

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2015, 2014, and 2013 is as follows:


	2015			2014 ⁽¹⁾			2013 ⁽¹⁾
Statutory U.S. federal income tax rate		34.0	%		34.0	%		34.0	%
Tax effect of Canadian items		(13.1	)		28.0			9.0
State income taxes, net of federal benefit		1.5			13.5			2.8
Nondeductible expenses and other		5.7			(11.5	)		(0.9	)
Change in valuation allowance, federal and state		(20.6	)		(72.0	)		(38.4	)

Effective tax rate		7.5	%		(8.0	)%		6.5	%

⁽¹⁾

Prior period amounts have been reclassified to conform to current year presentation.

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of our deferred tax assets (liabilities) as of December 31, 2015 and 2014 are as follows:


	2015			2014
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	21,985		$	28,547
Inventories		1,725			1,758
Capitalized research and development costs		4,803			4,528
Accruals and reserves currently not deductible		5,782			2,528
Acquired intangible assets		(2,725	)		(3,978	)
Depreciation and amortization		(367	)		(485	)
Stock-based compensation		6,371			5,369
Investment tax credit carryforward		(92	)		597
Research and development tax credit carryforward		1,885			1,833

Net deferred tax asset		39,367			40,697
Valuation allowance		(42,250	)		(44,072	)

Net deferred tax liability	$	(2,883	)	$	(3,375	)

In assessing the realizability of our net deferred tax asset, we consider all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent upon several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. In 2008, we established a full valuation allowance against our U.S. deferred tax asset, and management believes the full valuation allowance is still appropriate as of December 31, 2015 and 2014 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state income tax benefit was recorded for the years ended December 31, 2015, 2014, or 2013. The valuation allowance decreased by $1,822 in 2015 due to the use of net operating losses to offset U.S. taxable income.

Our Federal NOL carryforwards expire as follows:


Year of Expiration	NOLs
2018 - 2019	$	5,370
2020 - 2024		16,398
2025 - 2031		14,540
2032 - 2034		26,654

	$	62,962

The Tax Reform Act of 1986 contains provisions that limit the annual amount of NOLs available to be used in any given year in the event of a significant change in ownership. On September 29, 2000, two separate companies, STC Technologies, Inc. and Epitope, Inc., merged to form OraSure. A significant change in ownership, as defined by Section 382 of the Internal Revenue Code, occurred in connection with this merger. As such, the utilization of NOLs generated prior to September 29, 2000 is limited to approximately $13,700 per year. We do not believe that this limitation will have a material adverse impact on the utilization of our Federal NOL carryforwards in future years.

As of December 31, 2015, our gross unrecognized tax benefits totaled $2,088, and based upon the valuation allowance for our U.S. operations the recognition of any tax benefit would not impact our effective tax rate. We record interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2015, 2014 and 2013. As a result of our net operating loss carryforward position, we are subject to audit by the Internal Revenue Service since our inception, as well as by several state jurisdictions for the years ended September 30, 1998 through December 31, 2015.

A reconciliation of our unrecognized tax benefits is as follows:


	2015			2014			2013
Balance as of January 1	$	2,073		$	2,051		$	2,011
Additions for tax positions of prior periods		22			25			40
Reductions for tax positions of prior periods		(7	)		(3	)		—

Balance as of December 31	$	2,088		$	2,073		$	2,051

Stockholders' Equity

12 Months Ended

Dec. 31, 2015

Equity [Abstract]

Stockholders' Equity

8. STOCKHOLDERS’ EQUITY:

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended and restated (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue restricted stock, we issue new shares rather than purchase shares on the open market.

Under the terms of the Stock Plan, nonqualified options may be granted to eligible employees, including our officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.

As of December 31, 2015, 3,696 shares were available for future grants under the Stock Plan.

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2015			2014			2013
Risk-free interest rate⁽¹⁾		1.49	%		2.13	%		1.47	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		51	%		50	%		51	%
Expected life of stock options (in years)⁽²⁾		7			7			7

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Based upon historical experience.

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2015, 2014 and 2013 was $4.86, $3.03 and $3.58, respectively.

Compensation expense recognized in the financial statements related to stock options was as follows:


	Years Ended December 31,
	2015			2014			2013
Total compensation cost during the year	$	3,403		$	3,081		$	2,694
Amounts capitalized into inventory during the year		(153	)		(148	)		(128	)
Amounts recognized in cost of products sold for amounts previously capitalized		153			128			99

Amounts charged against income	$	3,403		$	3,061		$	2,665

The aggregate intrinsic value of options exercised during the years ended December 31, 2015, 2014, and 2013 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $329, $901, and $125, respectively.

The following table summarizes the stock option activity under the Stock Plan:


	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2013		4,644		$	7.64
Granted		984			6.94
Exercised		(80	)		5.07
Expired		(82	)		7.59
Forfeited		(195	)		7.87

Outstanding on December 31, 2013		5,271			7.54
Granted		1,202			5.77
Exercised		(249	)		5.09
Expired		(388	)		8.38
Forfeited		(96	)		7.43

Outstanding on December 31, 2014		5,740			7.22
Granted		773			9.28
Exercised		(74	)		5.46
Expired		(163	)		8.55
Forfeited		(60	)		8.07

Outstanding on December 31, 2015		6,216		$	7.46		6.0	$	2,405

Vested or expected to vest as of December 31, 2015		6,179		$	7.45		5.9	$	2,397

Exercisable on December 31, 2015		4,562		$	7.40		5.1	$	1,914

As of December 31, 2015, there was $5,519 of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 2.4 years.

Net cash proceeds from the exercise of stock options were $404, $1,115 and $409 for the years ended December 31, 2015, 2014, and 2013, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.

The following table summarizes information about stock options outstanding as of December 31, 2015:


Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$2.55 - $5.19		709		6.9	$	4.47		709	$	4.47
$5.47		5		9.7		5.47		—		—
$5.71		1,119		8.1		5.71		518		5.71
$5.72 - $6.37		216		6.2		5.96		172		5.96
$6.63		670		4.9		6.63		670		6.63
$6.67 - $6.99		29		8.0		6.93		13		6.92
$7.05		753		7.0		7.05		537		7.05
$7.33 - $8.28		844		2.4		8.02		832		8.03
$8.33 - $9.30		178		1.5		8.91		178		8.91
$9.31 - $12.14		1,693		6.3		10.14		933		10.76

		6,216		6.0	$	7.46		4,562	$	7.40

The Stock Plan also permits us to grant restricted shares of our common stock to eligible employees, including officers, and our outside directors. Generally, these shares are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by the Compensation Committee of our Board of Directors. The market value of these shares at the date of grant is recognized on a straight-line basis over the period during which the restrictions lapse. Compensation cost of $2,642, $2,663 and $2,878 related to restricted shares was recognized during the years ended December 31, 2015, 2014, and 2013, respectively.

The following table summarizes restricted stock award activity under the Stock Plan:


	Shares			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2013		670		$	8.19
Granted		438			6.30
Vested		(395	)		7.81
Forfeited		(60	)		8.27

Issued and unvested, December 31, 2013		653			7.15
Granted		506			5.82
Vested		(428	)		6.65
Forfeited		(24	)		7.38

Issued and unvested, December 31, 2014		707			6.50
Granted		362			8.25
Vested		(354	)		6.94
Forfeited		(18	)		8.01

Issued and unvested, December 31, 2015		697		$	7.14

Issued and expected to vest, December 31, 2015		697		$	7.14

As of December 31, 2015, there was $2,700 of unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of 1.6 years.

In connection with the vesting of restricted shares and exercise of stock options during the years ended December 31, 2015, 2014 and 2013, we purchased and immediately retired 133, 122 and 124 shares with aggregate values of $1,164, $639 and $829, respectively, in satisfaction of minimum tax withholding and exercise obligations.

Share Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. During the year ended December 31, 2015, we purchased and retired 777 shares of common stock at an average price of $6.34 per share for a total cost of $4,926. No shares were purchased and retired in 2014 or 2013.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Termination Settlement	12 Months Ended
Termination Settlement	Dec. 31, 2015
Extraordinary and Unusual Items [Abstract]
Termination Settlement	9. TERMINATION SETTLEMENT: On November 21, 2013, we terminated our assay collaboration agreement with Roche Diagnostics (“Roche”). Pursuant to this termination agreement, Roche paid us $8,300, which was recorded as a reduction of operating expense on our consolidated statement of operations for the quarter ended December 31, 2013. Roche agreed to provide certain transitional product support services to us and to supply certain of the assays developed under the collaboration on a transitional basis for up to five years following the termination. We had the right to stop the supply of assays prior to the end of this five-year period and to receive an additional payment from Roche of up to $5,500 depending on how early in that five-year period the supply obligation was ended. During the second quarter of 2014, we issued our final purchase order for fully-automated assays previously developed under the terminated collaboration and as such, recorded $5,500 as a reduction of operating expense in our consolidated statement of operations.

Business Segment Information

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Business Segment Information

10. BUSINESS SEGMENT INFORMATION:

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of diagnostic products, specimen collection devices and medical devices; and our molecular collection systems or “DNAG” business, which primarily consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet. OSUR also derives other revenues, including exclusivity payments for co-promotion rights and other licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of customers engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, animal and livestock genetic testing, and microbiome testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.

The following table summarizes operating segment information for the years ended December 31, 2015, 2014, and 2013, and asset information as of December 31, 2015 and 2014:


	Years Ended December 31,
	2015		2014			2013
Net revenues:
OSUR	$	89,795	$	82,686		$	78,559
DNAG		29,924		23,778			20,381

Total	$	119,719	$	106,464		$	98,940

Operating income (loss):
OSUR	$	3,558	$	(8,324	)	$	(12,849	)
DNAG		4,500		3,522			687

Total	$	8,058	$	(4,802	)	$	(12,162	)

Depreciation and amortization:
OSUR	$	3,015	$	3,254		$	3,225
DNAG		2,681		3,053			3,327

Total	$	5,696	$	6,307		$	6,552

Capital expenditures:
OSUR	$	1,645	$	2,170		$	1,687
DNAG		2,099		835			775

Total	$	3,744	$	3,005		$	2,462


	December 31,
	2015		2014
Total assets:
OSUR	$	137,082	$	136,542
DNAG		52,239		53,091

Total	$	189,321	$	189,633

Our products are sold principally in the United States and Europe.

The following table represents total net revenues by geographic area, based on the location of the customer:


	Years Ended December 31,
	2015		2014		2013
United States	$	96,522	$	82,256	$	77,194
Europe		13,535		13,913		11,081
Other regions		9,662		10,295		10,665

	$	119,719	$	106,464	$	98,940

The following table represents total long-lived assets by geographic area:


	December 31,
	2015		2014
United States	$	15,660	$	16,570
Canada		4,415		1,353
Other regions		8		11

	$	20,083	$	17,934

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

11. COMMITMENTS AND CONTINGENCIES:

Sublicense Agreement

In June 2004, we entered into a sublicense agreement with a third party pursuant to which we have been granted a limited, worldwide, non-exclusive sublicense to certain HIV-2 patents held by such party. Under the terms of this sublicense agreement, we are obligated to pay royalties based on a percentage of our net sales of certain products, which incorporate the technology covered by the licensed patents. Royalties are expensed as an element of cost of goods sold. Future minimum payments under this agreement are as follows:


2016	$	500
2017		500
2018		292

	$	1,292

Royalties from our commercial sale of products covered by the sublicense can be credited against these minimum royalty obligations.

Leases

We lease office space for our Canadian subsidiary and domestic warehouse facilities under operating lease agreements. Future payments required under these non-cancelable leases are as follows:


2016	$	362
2017		355
2018		351
2019		334
2020		362
Thereafter		724

	$	2,488

Rent expense for 2015, 2014 and 2013 was $731, $648, and $600, respectively.

Purchase Commitments

As of December 31, 2015, we had outstanding non-cancelable purchase commitments of $4,488 related to inventory, capital expenditures, and other goods or services.

Employment Agreements

Under terms of employment agreements with certain executive officers, which extend through 2016, we are required to pay each individual a base salary for continuing employment with us. The agreements require payments totaling $1,957 in 2016.

Litigation

From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions are not expected to have, either individually or in the aggregate, a material adverse effect on our future financial position or results of operations.

In May 2015, our subsidiary DNAG filed a complaint in the United States District Court for the District of Delaware against Ancestry.com DNA LLC (“Ancestry”) relating to the manufacture and sale by Ancestry of its oral fluid DNA collection device (the “Ancestry Device”). Ancestry previously purchased DNAG’s patented oral fluid DNA collection devices. The complaint alleges that the manufacture and sale by Ancestry of the Ancestry Device infringes U.S. Patent No. 8,221,381 B2, which is owned by DNAG. In addition, the complaint alleges that Ancestry has breached the terms of agreements under which Ancestry previously purchased DNAG products. The complaint also contains claims for conversion and trespass to chattel and includes an action to quiet title to the Ancestry Device and related patent applications. DNAG is requesting the court to grant injunctive relief and damages.

On October 20, 2015, Ancestry filed with the United States Patent and Trademark Office (“USPTO”) a Petition for Inter Partes Review of some, but not all, claims of U.S. Patent No. 8,221,381 B2. We expect the PTO to decide whether to initiate review of the DNAG patent in April 2016.

In July 2015, DNAG filed a complaint in the United States District Court for the District of Delaware against Spectrum DNA, Spectrum Solutions L.L.C. and Spectrum Packaging L.L.C. (collectively “Spectrum”) relating to the manufacture and sale by Spectrum of an oral fluid DNA collection device (the “Spectrum Device”). We believe the Spectrum Device is the same as the Ancestry device mentioned above and that Spectrum is the manufacturer of the Ancestry Device for Ancestry. The complaint alleges that the manufacture and sale by Spectrum of the Spectrum Device infringes U.S. patent number 8,221,381 B-2, which is owned by DNAG. DNAG is requesting the court to grant injunctive relief and damages.

Retirement Plans	12 Months Ended
Retirement Plans	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Retirement Plans	12. RETIREMENT PLANS: Substantially all of our U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for us to match employee contributions up to $4 per year. We contributed $587, $565, and $553 to the 401(k) Plan, net of forfeitures, in 2015, 2014, and 2013, respectively. In addition to our 401(k) plan, we offer a nonqualified deferred compensation plan to permit eligible highly compensated employees of the Company to defer receipt and taxation of their compensation each year. We also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2015 and 2014, the value of the assets associated with this plan was $1,324 and $1,234, respectively, and is included in other assets in our consolidated balance sheet. Our obligation related to the deferred compensation plan is included in other liabilities in our consolidated balance sheet. As of December 31, 2015 and 2014, our total obligation under this plan was $1,324 and $1,234, respectively. Substantially all regular full-time Canadian employees are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Revenue Canada. The RRSP also provides for DNAG to match employee contributions up to $2 per year. We contributed $134, $136, and $126 to the RRSP in 2015, 2014, and 2013, respectively.

Quarterly Data

12 Months Ended

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Quarterly Data

13. QUARTERLY DATA (Unaudited):

The following tables summarize the quarterly results of operations for each of the quarters in 2015 and 2014. These quarterly results are unaudited, but in the opinion of management, have been prepared on the same basis as our audited financial information and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the information set forth herein.


	2015 Results
	Three months ended
	March 31, 2015			June 30, 2015			September 30, 2015		December 31, 2015
Net revenues	$	27,088		$	30,388		$	29,861	$	32,382
Costs and expenses		27,379			27,667			28,325		28,290

Operating income (loss)		(291	)		2,721			1,536		4,092
Other income (expense), net		409			(95	)		81		379

Income before income taxes		118			2,626			1,617		4,471
Income tax expense (benefit)		5			658			147		(145	)

Net income	$	113		$	1,968		$	1,470	$	4,616

Earnings per share
Basic	$	0.00		$	0.03		$	0.03	$	0.08

Diluted	$	0.00		$	0.03		$	0.03	$	0.08


	2014 Results
	Three months ended
	March 31, 2014			June 30, 2014			September 30, 2014		December 31, 2014
Net revenues	$	23,537		$	26,401		$	27,845	$	28,681
Costs and expenses		29,155			23,904	⁽¹⁾		26,963		31,244

Operating income (loss)		(5,618	)		2,497			882		(2,563	)
Other income (expense), net		118			(142	)		268		287

Income (loss) before income taxes		(5,500	)		2,355			1,150		(2,276	)
Income tax expense (benefit)		131			(174	)		10		376

Net income (loss)	$	(5,631	)	$	2,529		$	1,140	$	(2,652	)

Earnings (loss) per share
Basic	$	(0.10	)	$	0.05		$	0.02	$	(0.05	)

Diluted	$	(0.10	)	$	0.04		$	0.02	$	(0.05	)

⁽¹⁾	Includes a $5,500 gain from the termination of the Company’s oral fluid assay collaboration with Roche Diagnostics, which was recorded as a reduction of operating expenses in the indicated period.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Principles of Consolidation and Basis of Presentation

Use of Estimates

Use of Estimates

Supplemental Cash Flow Information

Supplemental Cash Flow Information

In 2015, 2014 and 2013, we paid income taxes of $719, $31 and $27, respectively.

Short-Term Investments

Short-Term Investments

Accounts Receivable

Accounts Receivable

Inventories

Inventories

Property and Equipment

Property and Equipment

Intangible Assets

Intangible Assets

Goodwill

Goodwill

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Revenue Recognition

Revenue Recognition

We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick^® In-Home HIV test, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

Customer Sales Returns and Allowances

Customer Sales Returns and Allowances

Deferred Revenue

Deferred Revenue

Customer and Vendor Concentrations

Customer and Vendor Concentrations

Research and Development

Research and Development

Advertising Expenses

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2015, 2014, and 2013, we incurred $623, $6,910, and $17,142, respectively, in advertising expenses.

Stock-Based Compensation

Stock-Based Compensation

Income Taxes

Income Taxes

Foreign Currency Translation

Foreign Currency Translation

Earnings (Loss) Per Share

Earnings (Loss) Per Share

The computations of basic and diluted earnings (loss) per share are as follows:


	Year ended December 31,
	2015		2014			2013
Net income (loss)	$	8,167	$	(4,614	)	$	(11,190	)

Weighted average number of common shares outstanding:
Basic		56,397		55,949			55,555
Dilutive effect of stock options and restricted stock		449		—			—

Diluted		56,846		55,949			55,555

Earnings (loss) per share:
Basic	$	0.14	$	(0.08	)	$	(0.20	)

Diluted	$	0.14	$	(0.08	)	$	(0.20	)

Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss

Our accumulated other comprehensive loss for 2015, 2014, and 2013 consisted of foreign currency translation adjustments.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

As of December 31, 2015 and 2014, the carrying values of cash, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Level 1:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:

Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3:

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Computations of Basic and Diluted Earnings (Loss) per Share

The computations of basic and diluted earnings (loss) per share are as follows:


	Year ended December 31,
	2015		2014			2013
Net income (loss)	$	8,167	$	(4,614	)	$	(11,190	)

Weighted average number of common shares outstanding:
Basic		56,397		55,949			55,555
Dilutive effect of stock options and restricted stock		449		—			—

Diluted		56,846		55,949			55,555

Earnings (loss) per share:
Basic	$	0.14	$	(0.08	)	$	(0.20	)

Diluted	$	0.14	$	(0.08	)	$	(0.20	)

Inventories (Tables)

12 Months Ended

Dec. 31, 2015

Inventory Disclosure [Abstract]

Schedule of Inventories


	December 31,
	2015		2014
Raw materials	$	7,895	$	8,539
Work in process		333		898
Finished goods		5,014		6,326

	$	13,242	$	15,763

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment


	December 31,
	2015			2014
Land	$	1,118		$	1,118
Buildings and improvements		18,549			18,168
Machinery and equipment		21,263			20,768
Computer equipment and software		7,644			7,238
Furniture and fixtures		1,584			1,765
Construction in progress		2,938			293

		53,096			49,350
Less accumulated depreciation		(33,013	)		(31,416	)

	$	20,083		$	17,934

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in Goodwill

The changes in goodwill are as follows:


	December 31,
	2015			2014
Balance as of January 1	$	21,734		$	23,782
Decrease related to foreign currency translation		(3,484	)		(2,048	)

Balance as of December 31	$	18,250		$	21,734

Summary of Intangible Assets

Intangible assets consist of the following:


		December 31, 2015
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	9,051	$	(3,818	)	$	5,233
Patents and product rights	10		5,400		(3,358	)		2,042
Acquired technology	7		7,030		(4,172	)		2,858
Tradename	15		3,469		(1,011	)		2,458

		$	24,950	$	(12,359	)	$	12,591


		December 31, 2014
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	10,779	$	(3,508	)	$	7,271
Patents and product rights	3-10		10,449		(7,957	)		2,492
Acquired technology	7		8,372		(3,833	)		4,539
Tradename	15		4,132		(929	)		3,203

		$	33,732	$	(16,227	)	$	17,505

Summary of Patents and Products Rights

Patents and products rights are made up of the following:


	December 31,
	2015			2014
HIV-related	$	900		$	1,900
HCV-related		4,500			4,500
Lateral flow-related		—			1,500
Cryosurgery-related		—			2,549

		5,400			10,449
Less accumulated amortization		(3,358	)		(7,957	)

	$	2,042		$	2,492

Summary of Amortization Expense

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2016	$	2,704
2017		2,704
2018		2,701
2019		1,659
2020		1,451
Beyond		1,372

	$	12,591

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2015

Payables and Accruals [Abstract]

Schedule of Accrued Expenses


	December 31,
	2015		2014
Payroll and related benefits	$	6,311	$	6,620
Professional fees		1,014		480
Royalties		819		2,285
Other		2,268		1,747

	$	10,412	$	11,132

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) Before Income Tax Expense (Benefit)

Income (loss) before income tax expense (benefit) consists of the following:


	Years Ended December 31,
	2015		2014 ⁽¹⁾			2013 ⁽¹⁾
United States	$	5,302	$	(6,156	)	$	(10,554	)
Canada		3,530		1,885			(1,408	)

	$	8,832	$	(4,271	)	$	(11,962	)

Components of Income Tax Expense (Benefit)

The components of the income tax expense (benefit) are as follows:


	Years Ended December 31,
	2015			2014			2013
Current
Federal	$	—		$	—		$	—
State		—			—			—
Canada		617			49			—

		617			49			—

Deferred
Federal		1,511			(2,248	)		(4,280	)
State		311			(827	)		(323	)
Canada		48			294			(772	)

		1,870			(2,781	)		(5,375	)
Increase (decrease) in valuation allowance		(1,822	)		3,075			4,603

		48			294			(772	)

Total income tax expense (benefit)	$	665		$	343		$	(772	)

Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2015, 2014, and 2013 is as follows:


	2015			2014 ⁽¹⁾			2013 ⁽¹⁾
Statutory U.S. federal income tax rate		34.0	%		34.0	%		34.0	%
Tax effect of Canadian items		(13.1	)		28.0			9.0
State income taxes, net of federal benefit		1.5			13.5			2.8
Nondeductible expenses and other		5.7			(11.5	)		(0.9	)
Change in valuation allowance, federal and state		(20.6	)		(72.0	)		(38.4	)

Effective tax rate		7.5	%		(8.0	)%		6.5	%

Components of Total Deferred Tax Assets (Liabilities)

Significant components of our deferred tax assets (liabilities) as of December 31, 2015 and 2014 are as follows:


	2015			2014
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	21,985		$	28,547
Inventories		1,725			1,758
Capitalized research and development costs		4,803			4,528
Accruals and reserves currently not deductible		5,782			2,528
Acquired intangible assets		(2,725	)		(3,978	)
Depreciation and amortization		(367	)		(485	)
Stock-based compensation		6,371			5,369
Investment tax credit carryforward		(92	)		597
Research and development tax credit carryforward		1,885			1,833

Net deferred tax asset		39,367			40,697
Valuation allowance		(42,250	)		(44,072	)

Net deferred tax liability	$	(2,883	)	$	(3,375	)

Expiry Details of Federal Net Operating Losses Carryforwards

Our Federal NOL carryforwards expire as follows:


Year of Expiration	NOLs
2018 - 2019	$	5,370
2020 - 2024		16,398
2025 - 2031		14,540
2032 - 2034		26,654

	$	62,962

Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits

A reconciliation of our unrecognized tax benefits is as follows:


	2015			2014			2013
Balance as of January 1	$	2,073		$	2,051		$	2,011
Additions for tax positions of prior periods		22			25			40
Reductions for tax positions of prior periods		(7	)		(3	)		—

Balance as of December 31	$	2,088		$	2,073		$	2,051

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2015

Equity [Abstract]

Weighted-Average Assumptions for Fair Value Measurement

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2015			2014			2013
Risk-free interest rate⁽¹⁾		1.49	%		2.13	%		1.47	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		51	%		50	%		51	%
Expected life of stock options (in years)⁽²⁾		7			7			7

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Based upon historical experience.

Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options

Compensation expense recognized in the financial statements related to stock options was as follows:


	Years Ended December 31,
	2015			2014			2013
Total compensation cost during the year	$	3,403		$	3,081		$	2,694
Amounts capitalized into inventory during the year		(153	)		(148	)		(128	)
Amounts recognized in cost of products sold for amounts previously capitalized		153			128			99

Amounts charged against income	$	3,403		$	3,061		$	2,665

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity under the Stock Plan:


	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2013		4,644		$	7.64
Granted		984			6.94
Exercised		(80	)		5.07
Expired		(82	)		7.59
Forfeited		(195	)		7.87

Outstanding on December 31, 2013		5,271			7.54
Granted		1,202			5.77
Exercised		(249	)		5.09
Expired		(388	)		8.38
Forfeited		(96	)		7.43

Outstanding on December 31, 2014		5,740			7.22
Granted		773			9.28
Exercised		(74	)		5.46
Expired		(163	)		8.55
Forfeited		(60	)		8.07

Outstanding on December 31, 2015		6,216		$	7.46		6.0	$	2,405

Vested or expected to vest as of December 31, 2015		6,179		$	7.45		5.9	$	2,397

Exercisable on December 31, 2015		4,562		$	7.40		5.1	$	1,914

Schedule of Currently Outstanding and Exercisable Stock Options

The following table summarizes information about stock options outstanding as of December 31, 2015:


Options outstanding							Options exercisable
Range of exercise prices	Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$2.55 - $5.19		709		6.9	$	4.47		709	$	4.47
$5.47		5		9.7		5.47		—		—
$5.71		1,119		8.1		5.71		518		5.71
$5.72 - $6.37		216		6.2		5.96		172		5.96
$6.63		670		4.9		6.63		670		6.63
$6.67 - $6.99		29		8.0		6.93		13		6.92
$7.05		753		7.0		7.05		537		7.05
$7.33 - $8.28		844		2.4		8.02		832		8.03
$8.33 - $9.30		178		1.5		8.91		178		8.91
$9.31 - $12.14		1,693		6.3		10.14		933		10.76

		6,216		6.0	$	7.46		4,562	$	7.40

Summary of Restricted Stock Award Activity under Stock Plan

The following table summarizes restricted stock award activity under the Stock Plan:


	Shares			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2013		670		$	8.19
Granted		438			6.30
Vested		(395	)		7.81
Forfeited		(60	)		8.27

Issued and unvested, December 31, 2013		653			7.15
Granted		506			5.82
Vested		(428	)		6.65
Forfeited		(24	)		7.38

Issued and unvested, December 31, 2014		707			6.50
Granted		362			8.25
Vested		(354	)		6.94
Forfeited		(18	)		8.01

Issued and unvested, December 31, 2015		697		$	7.14

Issued and expected to vest, December 31, 2015		697		$	7.14

Business Segment Information (Tables)

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the years ended December 31, 2015, 2014, and 2013, and asset information as of December 31, 2015 and 2014:


	Years Ended December 31,
	2015		2014			2013
Net revenues:
OSUR	$	89,795	$	82,686		$	78,559
DNAG		29,924		23,778			20,381

Total	$	119,719	$	106,464		$	98,940

Operating income (loss):
OSUR	$	3,558	$	(8,324	)	$	(12,849	)
DNAG		4,500		3,522			687

Total	$	8,058	$	(4,802	)	$	(12,162	)

Depreciation and amortization:
OSUR	$	3,015	$	3,254		$	3,225
DNAG		2,681		3,053			3,327

Total	$	5,696	$	6,307		$	6,552

Capital expenditures:
OSUR	$	1,645	$	2,170		$	1,687
DNAG		2,099		835			775

Total	$	3,744	$	3,005		$	2,462


	December 31,
	2015		2014
Total assets:
OSUR	$	137,082	$	136,542
DNAG		52,239		53,091

Total	$	189,321	$	189,633

Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area

The following table represents total net revenues by geographic area, based on the location of the customer:


	Years Ended December 31,
	2015		2014		2013
United States	$	96,522	$	82,256	$	77,194
Europe		13,535		13,913		11,081
Other regions		9,662		10,295		10,665

	$	119,719	$	106,464	$	98,940

The following table represents total long-lived assets by geographic area:


	December 31,
	2015		2014
United States	$	15,660	$	16,570
Canada		4,415		1,353
Other regions		8		11

	$	20,083	$	17,934

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Schedule for Future Minimum Payments under Sublicense Agreement

Future minimum payments under this agreement are as follows:


2016	$	500
2017		500
2018		292

	$	1,292

Schedule for Future Minimum Lease Payments under Operating Lease Agreements

Future payments required under these non-cancelable leases are as follows:


2016	$	362
2017		355
2018		351
2019		334
2020		362
Thereafter		724

	$	2,488

Quarterly Data (Tables)

12 Months Ended

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Summary of Quarterly Results of Operations


	2015 Results
	Three months ended
	March 31, 2015			June 30, 2015			September 30, 2015		December 31, 2015
Net revenues	$	27,088		$	30,388		$	29,861	$	32,382
Costs and expenses		27,379			27,667			28,325		28,290

Operating income (loss)		(291	)		2,721			1,536		4,092
Other income (expense), net		409			(95	)		81		379

Income before income taxes		118			2,626			1,617		4,471
Income tax expense (benefit)		5			658			147		(145	)

Net income	$	113		$	1,968		$	1,470	$	4,616

Earnings per share
Basic	$	0.00		$	0.03		$	0.03	$	0.08

Diluted	$	0.00		$	0.03		$	0.03	$	0.08


	2014 Results
	Three months ended
	March 31, 2014			June 30, 2014			September 30, 2014		December 31, 2014
Net revenues	$	23,537		$	26,401		$	27,845	$	28,681
Costs and expenses		29,155			23,904	⁽¹⁾		26,963		31,244

Operating income (loss)		(5,618	)		2,497			882		(2,563	)
Other income (expense), net		118			(142	)		268		287

Income (loss) before income taxes		(5,500	)		2,355			1,150		(2,276	)
Income tax expense (benefit)		131			(174	)		10		376

Net income (loss)	$	(5,631	)	$	2,529		$	1,140	$	(2,652	)

Earnings (loss) per share
Basic	$	(0.10	)	$	0.05		$	0.02	$	(0.05	)

Diluted	$	(0.10	)	$	0.04		$	0.02	$	(0.05	)

⁽¹⁾	Includes a $5,500 gain from the termination of the Company’s oral fluid assay collaboration with Roche Diagnostics, which was recorded as a reduction of operating expenses in the indicated period.

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Thousands					1 Months Ended	12 Months Ended
	Dec. 31, 2015	Jun. 12, 2015	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jan. 01, 2013
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income taxes paid						$ 719,000	$ 31,000	$ 27,000
Increase or decrease in allowance for doubtful accounts						341,000	253,000	18,000
Write-offs against allowance for doubtful account						$ 0	0	0
Accruals for purchases of property and equipment	$ 1,370,000		$ 217,000	$ 0
Expiration date of rights agreement						Dec. 31, 2019
Maximum value of grant revenue from clinical and regulatory activities		$ 10,400,000
Initial grant revenue from clinical and regulatory activities		1,800,000
Remaining grant revenue from clinical and regulatory activities		$ 8,600,000
Period of grant		3 years
Additional contract revenue from clinical and regulatory activities					$ 7,200,000
Reserve for sales return and allowances						$ 310,000	437,000
Deferred revenue	9,735,000		8,043,000			9,735,000	8,043,000
Advertising expenses						623,000	6,910,000	17,142,000
Net foreign exchange gains						1,005,000	273,000	68,000
Accumulated foreign currency adjustments included in other comprehensive loss amounted	(7,791,000)		(4,051,000)	(3,131,000)		(7,791,000)	(4,051,000)	(3,131,000)
Cash and cash equivalents	94,094,000		92,867,000	$ 93,191,000		94,094,000	92,867,000	$ 93,191,000	$ 87,888,000
Fair value of plan assets	1,324,000		1,234,000			1,324,000	1,234,000
Available-for-sale securities, fair values	7,225,000		5,000,000			7,225,000	5,000,000
Money Market Fund [Member] \| Level I Instrument [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	65,509,000		64,361,000			$ 65,509,000	$ 64,361,000
Common Stock Options and Unvested Restricted Stock [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation						4,756	6,447	5,924
Collaborative Arrangement Co-promotion [Member] \| OraQuick HCV [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue recognition, milestone method description						We may be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the term of the agreement. The first performance-based milestone period ended on December 31, 2015
Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk						12.00%	0.00%	0.00%
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	784,000		613,000			$ 784,000	$ 613,000
AbbVie [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	8,951,000		7,430,000			8,951,000	7,430,000
Guaranteed Investment Certificates [Member] \| Level I Instrument [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Available-for-sale securities, amortized cost	7,225,000		7,225,000			7,225,000	7,225,000
Available-for-sale securities, fair values	$ 5,000,000		$ 5,000,000			5,000,000	$ 5,000,000
Other [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Contract revenues from clinical and regulatory activities						$ 1,783,000
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets						15 years
Maximum [Member] \| Collaborative Arrangement Co-promotion [Member] \| OraQuick HCV [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Payments received for sale of exclusive rights						$ 75,000,000
Additional annual payments to be received for sale of exclusive rights						$ 55,500,000
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets						40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets						10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets						10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets						10 years
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets						1 year
Minimum [Member] \| Collaborative Arrangement Co-promotion [Member] \| OraQuick HCV [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Additional annual payments to be received for sale of exclusive rights						$ 3,500,000
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets						20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets						2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets						2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets						2 years
DNA Genotek [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of third-party suppliers to manufacture DNAG's products						2

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings (Loss) per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
NET INCOME (LOSS)	$ 4,616	$ 1,470	$ 1,968	$ 113	$ (2,652)	$ 1,140	$ 2,529	$ (5,631)	$ 8,167	$ (4,614)	$ (11,190)
Weighted average number of common shares outstanding:
BASIC									56,397	55,949	55,555
Dilutive effect of stock options and restricted stock									449
Diluted									56,846	55,949	55,555
BASIC	$ 0.08	$ 0.03	$ 0.03	$ 0.00	$ (0.05)	$ 0.02	$ 0.05	$ (0.10)	$ 0.14	$ (0.08)	$ (0.20)
DILUTED	$ 0.08	$ 0.03	$ 0.03	$ 0.00	$ (0.05)	$ 0.02	$ 0.04	$ (0.10)	$ 0.14	$ (0.08)	$ (0.20)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory, Net [Abstract]
Raw materials	$ 7,895	$ 8,539
Work in process	333	898
Finished goods	5,014	6,326
Inventories	$ 13,242	$ 15,763

Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 53,096	$ 49,350
Less accumulated depreciation	(33,013)	(31,416)
Property plant and equipment Net	20,083	17,934
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	1,118	1,118
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	18,549	18,168
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	21,263	20,768
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	7,644	7,238
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	1,584	1,765
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 2,938	$ 293

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,992	$ 3,123	$ 3,026

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Roll Forward]
Beginning Balance	$ 21,734	$ 23,782
Decrease related to foreign currency translation	(3,484)	(2,048)
Ending Balance	$ 18,250	$ 21,734

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 24,950	$ 33,732
Intangible Assets, Accumulated Amortization	(12,359)	(16,227)
Intangible Assets, Net	$ 12,591	$ 17,505
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	1 year
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 9,051	$ 10,779
Intangible Assets, Accumulated Amortization	(3,818)	(3,508)
Intangible Assets, Net	$ 5,233	7,271
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years
Intangible Assets, Gross	$ 5,400	10,449
Intangible Assets, Accumulated Amortization	(3,358)	(7,957)
Intangible Assets, Net	$ 2,042	$ 2,492
Patents and Product Rights [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)		3 years
Patents and Product Rights [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)		10 years
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	7 years	7 years
Intangible Assets, Gross	$ 7,030	$ 8,372
Intangible Assets, Accumulated Amortization	(4,172)	(3,833)
Intangible Assets, Net	$ 2,858	$ 4,539
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years	15 years
Intangible Assets, Gross	$ 3,469	$ 4,132
Intangible Assets, Accumulated Amortization	(1,011)	(929)
Intangible Assets, Net	$ 2,458	$ 3,203

Goodwill and Other Intangible Assets - Summary of Patents and Products Rights (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	$ 24,950	$ 33,732
Less accumulated amortization	(12,359)	(16,227)
Patent and products right, Net	12,591	17,505
HIV-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	900	1,900
HCV-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	4,500	4,500
Lateral Flow-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount		1,500
Cryosurgery-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount		2,549
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	5,400	10,449
Less accumulated amortization	(3,358)	(7,957)
Patent and products right, Net	$ 2,042	$ 2,492

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 2,704	$ 3,184	$ 3,526

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) $ in Thousands	Dec. 31, 2015 USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2016	$ 2,704
2017	2,704
2018	2,701
2019	1,659
2020	1,451
Beyond	1,372
Total	$ 12,591

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$ 6,311	$ 6,620
Professional fees	1,014	480
Royalties	819	2,285
Other	2,268	1,747
Accrued Expenses, Total	$ 10,412	$ 11,132

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]
United States	$ 5,302	$ (6,156)	$ (10,554)
Canada	3,530	1,885	(1,408)
Income (loss) before income taxes	$ 8,832	$ (4,271)	$ (11,962)

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current
Federal									$ 0	$ 0	$ 0
State									0	0	0
Canada									617	49
Total current income tax expense (benefit)									617	49
Deferred
Federal									1,511	(2,248)	(4,280)
State									311	(827)	(323)
Canada									48	294	(772)
Total deferred income tax expense (benefit)									1,870	(2,781)	(5,375)
Increase (decrease) in valuation allowance									(1,822)	3,075	4,603
Deferred income taxes									48	294	(772)
Total income tax expense (benefit)	$ (145)	$ 147	$ 658	$ 5	$ 376	$ 10	$ (174)	$ 131	$ 665	$ 343	$ (772)

Income Taxes - Additional Information (Detail) $ in Thousands		12 Months Ended
	Sep. 29, 2000 USD ($) Companies	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Jan. 01, 2013 USD ($)
Income Tax Disclosure [Abstract]
Foreign tax expense		$ 665	$ 343	$ 772
U.S. federal income tax benefits		0	0	0
U.S. state income tax benefits		0	0	0
Decrease in valuation allowance		(1,822)	3,075	4,603
Number of companies merged \| Companies	2
Utilization of NOLs generated prior limited to	$ 13,700
Gross unrecognized tax benefits		$ 2,088	$ 2,073	$ 2,051	$ 2,011

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	34.00%	34.00%	34.00%
Tax effect of Canadian items	(13.10%)	28.00%	9.00%
State income taxes, net of federal benefit	1.50%	13.50%	2.80%
Nondeductible expenses and other	5.70%	(11.50%)	(0.90%)
Change in valuation allowance, federal and state	(20.60%)	(72.00%)	(38.40%)
Effective tax rate	7.50%	(8.00%)	6.50%

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 21,985	$ 28,547
Inventories	1,725	1,758
Capitalized research and development costs	4,803	4,528
Accruals and reserves currently not deductible	5,782	2,528
Acquired intangible assets	(2,725)	(3,978)
Depreciation and amortization	(367)	(485)
Stock-based compensation	6,371	5,369
Investment tax credit carryforward		597
Investment tax credit carryforward	(92)
Research and development tax credit carryforward	1,885	1,833
Net deferred tax asset	39,367	40,697
Valuation allowance	(42,250)	(44,072)
Net deferred tax liability	$ (2,883)	$ (3,375)

Income Taxes - Expiry Details of Federal Net Operating Losses Carryforwards (Detail) $ in Thousands	Dec. 31, 2015 USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 62,962
2018-2019 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	5,370
2020-2024 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	16,398
2025-2031 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	14,540
2032 - 2034 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 26,654

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance as of January 1	$ 2,073	$ 2,051	$ 2,011
Additions for tax positions of prior periods	22	25	40
Reductions for tax positions of prior periods	(7)	(3)
Balance as of December 31	$ 2,088	$ 2,073	$ 2,051

Stockholders' Equity - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price	75.00%
Granted exercise periods	10 years
Option vesting period	4 years
Vesting of Options	Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.
Shares available for future grants under the Stock Plan	3,696,000
Proceeds from exercise of stock options	$ 404,000	$ 1,115,000	$ 409,000
Income tax benefit realized from stock option exercises during period	0	0	0
Total compensation cost	6,045,000	5,744,000	5,572,000
Amount share repurchase program of common shares				$ 25,000,000
Total cost of common stock purchased and retired	$ 6,090,000	$ 639,000	$ 829,000
Share Repurchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	777	0	0
Average price of common stock	$ 6.34
Total cost of common stock purchased and retired	$ 4,926,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value of stock options granted	$ 4.86	$ 3.03	$ 3.58
Aggregate intrinsic value of options exercised	$ 329,000	$ 901,000	$ 125,000
Unrecognized compensation expense related to unvested option awards	$ 5,519,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	2 years 4 months 24 days
Proceeds from exercise of stock options	$ 404,000	1,115,000	409,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 7 months 6 days
Total compensation cost	$ 2,642,000	$ 2,663,000	$ 2,878,000
Unrecognized compensation expense related to unvested restricted stock awards	$ 2,700,000
Vesting of restricted shares and exercise of stock options, withholding and exercise obligations	133,000	122,000	124,000
Restricted shares of common stock and stock options, aggregate values	$ 1,164,000	$ 639,000	$ 829,000

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	1.49%	2.13%	1.47%
Expected dividend yield	0.00%	0.00%	0.00%
Expected stock price volatility	51.00%	50.00%	51.00%
Expected life of stock options (in years)	7 years	7 years	7 years

Stockholders' Equity - Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Total compensation cost during the year	$ 3,403	$ 3,081	$ 2,694
Amounts capitalized into inventory during the year	(153)	(148)	(128)
Amounts recognized in cost of products sold for amounts previously capitalized	153	128	99
Amounts charged against income	$ 3,403	$ 3,061	$ 2,665

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding, Beginning Balance	5,740	5,271	4,644
Options, Granted	773	1,202	984
Options, Exercised	(74)	(249)	(80)
Options, Expired	(163)	(388)	(82)
Options, Forfeited	(60)	(96)	(195)
Options, Outstanding, Ending Balance	6,216	5,740	5,271
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 7.22	$ 7.54	$ 7.64
Options, Vested or expected to vest	6,179
Weighted-Average Exercise Price Per Share, Granted	$ 9.28	5.77	6.94
Options, Exercisable	4,562
Weighted-Average Exercise Price Per Share, Exercised	$ 5.46	5.09	5.07
Weighted-Average Exercise Price Per Share, Expired	8.55	8.38	7.59
Weighted-Average Exercise Price Per Share, Forfeited	8.07	7.43	7.87
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance	7.46	$ 7.22	$ 7.54
Weighted-Average Exercise Price Per Share, Vested or expected to vest	7.45
Weighted-Average Exercise Price Per Share, Exercisable	$ 7.40
Weighted-Average Remaining Contractual Term, Outstanding	6 years
Weighted-Average Remaining Contractual Term, Vested or expected to vest	5 years 10 months 24 days
Weighted-Average Remaining Contractual Term, Exercisable	5 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding	$ 2,405
Aggregate Intrinsic Value, Vested or expected to vest	2,397
Aggregate Intrinsic Value, Exercisable	$ 1,914

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2015 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding, Options outstanding \| shares	6,216
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years
Weighted-Average Exercise Price Per Share, Options outstanding	$ 7.46
Number Exercisable, Options exercisable \| shares	4,562
Weighted-Average Exercise Price Per Share, Options exercisable	$ 7.40
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	2.55
Range of exercise prices, Upper Range Limit	$ 5.19
Number Outstanding, Options outstanding \| shares	709
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 10 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 4.47
Number Exercisable, Options exercisable \| shares	709
Weighted-Average Exercise Price Per Share, Options exercisable	$ 4.47
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 5.47
Number Outstanding, Options outstanding \| shares	5
Weighted-Average Remaining Contractual Term (in years), Options outstanding	9 years 8 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.47
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 5.71
Number Outstanding, Options outstanding \| shares	1,119
Weighted-Average Remaining Contractual Term (in years), Options outstanding	8 years 1 month 6 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.71
Number Exercisable, Options exercisable \| shares	518
Weighted-Average Exercise Price Per Share, Options exercisable	$ 5.71
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	5.72
Range of exercise prices, Upper Range Limit	$ 6.37
Number Outstanding, Options outstanding \| shares	216
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 2 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.96
Number Exercisable, Options exercisable \| shares	172
Weighted-Average Exercise Price Per Share, Options exercisable	$ 5.96
Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 6.63
Number Outstanding, Options outstanding \| shares	670
Weighted-Average Remaining Contractual Term (in years), Options outstanding	4 years 10 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 6.63
Number Exercisable, Options exercisable \| shares	670
Weighted-Average Exercise Price Per Share, Options exercisable	$ 6.63
Range Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	6.67
Range of exercise prices, Upper Range Limit	$ 6.99
Number Outstanding, Options outstanding \| shares	29
Weighted-Average Remaining Contractual Term (in years), Options outstanding	8 years
Weighted-Average Exercise Price Per Share, Options outstanding	$ 6.93
Number Exercisable, Options exercisable \| shares	13
Weighted-Average Exercise Price Per Share, Options exercisable	$ 6.92
Range Seven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 7.05
Number Outstanding, Options outstanding \| shares	753
Weighted-Average Remaining Contractual Term (in years), Options outstanding	7 years
Weighted-Average Exercise Price Per Share, Options outstanding	$ 7.05
Number Exercisable, Options exercisable \| shares	537
Weighted-Average Exercise Price Per Share, Options exercisable	$ 7.05
Range Eight [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	7.33
Range of exercise prices, Upper Range Limit	$ 8.28
Number Outstanding, Options outstanding \| shares	844
Weighted-Average Remaining Contractual Term (in years), Options outstanding	2 years 4 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 8.02
Number Exercisable, Options exercisable \| shares	832
Weighted-Average Exercise Price Per Share, Options exercisable	$ 8.03
Range Nine [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	8.33
Range of exercise prices, Upper Range Limit	$ 9.30
Number Outstanding, Options outstanding \| shares	178
Weighted-Average Remaining Contractual Term (in years), Options outstanding	1 year 6 months
Weighted-Average Exercise Price Per Share, Options outstanding	$ 8.91
Number Exercisable, Options exercisable \| shares	178
Weighted-Average Exercise Price Per Share, Options exercisable	$ 8.91
Range Ten [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	9.31
Range of exercise prices, Upper Range Limit	$ 12.14
Number Outstanding, Options outstanding \| shares	1,693
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 3 months 18 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.14
Number Exercisable, Options exercisable \| shares	933
Weighted-Average Exercise Price Per Share, Options exercisable	$ 10.76

Stockholders' Equity - Summary of Restricted Stock Award Activity Under Stock Plan (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	707	653	670
Shares, Granted	362	506	438
Shares, Vested	(354)	(428)	(395)
Shares, Forfeited	(18)	(24)	(60)
Shares, Issued and unvested, Ending Balance	697	707	653
Shares, Issued and expected to vest	697
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance	$ 6.50	$ 7.15	$ 8.19
Weighted-Average Grant Date Fair Value, Granted	8.25	5.82	6.30
Weighted-Average Grant Date Fair Value, Vested	6.94	6.65	7.81
Weighted-Average Grant Date Fair Value, Forfeited	8.01	7.38	8.27
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance	7.14	$ 6.50	$ 7.15
Weighted-Average Grant Date Fair Value, Issued and expected to vest	$ 7.14

Termination Settlement - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Unusual or Infrequent Item [Line Items]
Gain on contract termination settlement	$ 5,500,000	$ 8,300,000		$ 5,500,000	$ 8,300,000
Termination date			Nov. 21, 2013
Notice period after termination of contract			5 years
Maximum [Member]
Unusual or Infrequent Item [Line Items]
Additional payment received relating to termination of contract			$ 5,500,000

Business Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net revenues	$ 32,382	$ 29,861	$ 30,388	$ 27,088	$ 28,681	$ 27,845	$ 26,401	$ 23,537	$ 119,719	$ 106,464	$ 98,940
Operating income (loss)	4,092	$ 1,536	$ 2,721	$ (291)	(2,563)	$ 882	$ 2,497	$ (5,618)	8,058	(4,802)	(12,162)
Depreciation and amortization									5,696	6,307	6,552
Capital expenditures									3,744	3,005	2,462
Total assets	189,321				189,633				189,321	189,633
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues									89,795	82,686	78,559
Operating income (loss)									3,558	(8,324)	(12,849)
Depreciation and amortization									3,015	3,254	3,225
Capital expenditures									1,645	2,170	1,687
Total assets	137,082				136,542				137,082	136,542
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues									29,924	23,778	20,381
Operating income (loss)									4,500	3,522	687
Depreciation and amortization									2,681	3,053	3,327
Capital expenditures									2,099	835	$ 775
Total assets	$ 52,239				$ 53,091				$ 52,239	$ 53,091

Business Segment Information - Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$ 32,382	$ 29,861	$ 30,388	$ 27,088	$ 28,681	$ 27,845	$ 26,401	$ 23,537	$ 119,719	$ 106,464	$ 98,940
Long-lived assets	20,083				17,934				20,083	17,934
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									96,522	82,256	77,194
Long-lived assets	15,660				16,570				15,660	16,570
Europe [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									13,535	13,913	11,081
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									9,662	10,295	$ 10,665
Long-lived assets	8				11				8	11
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 4,415				$ 1,353				$ 4,415	$ 1,353

Commitments and Contingencies - Schedule for Future Minimum Payments under Sublicense Agreement (Detail) $ in Thousands	Dec. 31, 2015 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2016	$ 500
2017	500
2018	292
Total	$ 1,292

Commitments and Contingencies - Schedule for Future Minimum Lease Payments under Operating Lease Agreements (Detail) $ in Thousands	Dec. 31, 2015 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2016	$ 362
2017	355
2018	351
2019	334
2020	362
Thereafter	724
Total	$ 2,488

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Contractual Obligation Fiscal Year Maturity [Line Items]
Rent expense	$ 731	$ 648	$ 600
Outstanding non-cancellable purchase commitments		$ 4,488
Required salary payment as per agreements with employees, next year	500
Employment Agreements [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Required salary payment as per agreements with employees, next year	$ 1,957

Retirement Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	$ 4,000
Contributed to plan, net of forfeitures	587,000	$ 565,000	$ 553,000
Value of the assets associated with the plan	1,324,000	1,234,000
Total obligation under plan	1,324,000	1,234,000
RRSP [Member] \| DNA Genotek [Member]
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	2,000
Contributed to plan, net of forfeitures	$ 134,000	$ 136,000	$ 126,000

Quarterly Data - Summary of Quarterly Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 32,382	$ 29,861	$ 30,388	$ 27,088	$ 28,681	$ 27,845	$ 26,401	$ 23,537	$ 119,719	$ 106,464	$ 98,940
Costs and expenses	28,290	28,325	27,667	27,379	31,244	26,963	23,904	29,155
Operating income (loss)	4,092	1,536	2,721	(291)	(2,563)	882	2,497	(5,618)	8,058	(4,802)	(12,162)
Other income (expense), net	379	81	(95)	409	287	268	(142)	118	774	531	200
Income (loss) before income taxes	4,471	1,617	2,626	118	(2,276)	1,150	2,355	(5,500)	8,832	(4,271)	(11,962)
INCOME TAX EXPENSE (BENEFIT)	(145)	147	658	5	376	10	(174)	131	665	343	(772)
NET INCOME (LOSS)	$ 4,616	$ 1,470	$ 1,968	$ 113	$ (2,652)	$ 1,140	$ 2,529	$ (5,631)	$ 8,167	$ (4,614)	$ (11,190)
Earnings (loss) per share
BASIC	$ 0.08	$ 0.03	$ 0.03	$ 0.00	$ (0.05)	$ 0.02	$ 0.05	$ (0.10)	$ 0.14	$ (0.08)	$ (0.20)
DILUTED	$ 0.08	$ 0.03	$ 0.03	$ 0.00	$ (0.05)	$ 0.02	$ 0.04	$ (0.10)	$ 0.14	$ (0.08)	$ (0.20)

Quarterly Data - Summary of Quarterly Results of Operations (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Gain on contract termination	$ 5,500	$ 8,300	$ 5,500	$ 8,300